The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
about
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
P2860
The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The evolving role of cytotoxic ...... th metastatic prostate cancer.
@en
type
label
The evolving role of cytotoxic ...... th metastatic prostate cancer.
@en
prefLabel
The evolving role of cytotoxic ...... th metastatic prostate cancer.
@en
P2093
P2860
P1476
The evolving role of cytotoxic ...... th metastatic prostate cancer.
@en
P2093
Beerinder Karir
Elan Diamond
María del Carmen Garcias
Scott T Tagawa
P2860
P2888
P356
10.1007/S11864-014-0324-2
P577
2015-02-01T00:00:00Z
P6179
1011824170